论文部分内容阅读
慢性髓细胞性白血病(CML)应用伊马替尼后,明显改善了预后,但治疗失败的患者则预后不良。为改善这些患者的预后,一方面需要加强细胞遗传学和分子生物学监测,及早发现治疗失败并给予干预。另一方面,对于大多数治疗失败的患者,二代酪氨酸激酶抑制剂(TKIs)是合适的选择,如果就目前临床上两种二代TKIs进行比较,总体看来尼洛替尼好于达沙替尼。
After Imatinib is used in chronic myelogenous leukemia (CML), the prognosis is significantly improved, but the prognosis is poor in patients with failed treatment. To improve the prognosis of these patients, on the one hand need to strengthen cytogenetics and molecular biology monitoring, early detection of treatment failure and intervention. On the other hand, second-generation tyrosine kinase inhibitors (TKIs) are a suitable choice for most treatment failure patients. If the current clinical comparison of two second-generation TKIs shows that nilotinib is generally better than Dasatinib.